Clinical Trial Detail

NCT ID NCT02475681
Title Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

chronic lymphocytic leukemia

Therapies

Acalabrutinib

Chlorambucil

Obinutuzumab

Age Groups: adult

No variant requirements are available.